513fb61a-1339-45d2-8963-6337e3aff5df
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 51
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.560
- MYC_TARGETS_V1+0.540
- OXIDATIVE_PHOSPHORYLATION+0.480
- E2F_TARGETS+0.410
- DNA_REPAIR+0.360
- FATTY_ACID_METABOLISM+0.310
- UNFOLDED_PROTEIN_RESPONSE+0.280
- G2M_CHECKPOINT+0.270
- PEROXISOME+0.240
- SPERMATOGENESIS+0.220
Top 10 suppressed
- INFLAMMATORY_RESPONSE-0.550
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.540
- IL6_JAK_STAT3_SIGNALING-0.500
- INTERFERON_GAMMA_RESPONSE-0.470
- HEDGEHOG_SIGNALING-0.450
- KRAS_SIGNALING_UP-0.440
- TNFA_SIGNALING_VIA_NFKB-0.430
- ALLOGRAFT_REJECTION-0.420
- UV_RESPONSE_DN-0.410
- ANGIOGENESIS-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 64935b9c-623d-40d4-bd89-f2af006b1f92 | — | — | 0.948 |
| 2 | SRR12475110 | — | — | 0.937 |
| 3 | AUR-AFR3-TTM1-A-1-1-R-A743-41 | — | C | 0.928 |
| 4 | a8ce7460-8ccd-4638-a854-55c4068af6ec | — | — | 0.924 |
| 5 | TCGA-85-8070-01A-11R-2247-07 | — | cohortSQ2 | 0.923 |
| 6 | f8d9864e-e148-4e60-9d9d-3df2897050cd | — | — | 0.921 |
| 7 | TCGA-CQ-6225-01A-11R-1915-07 | — | — | 0.921 |
| 8 | 2d8cab40-0dda-4d6d-a9ba-83a82a7e1c15 | — | — | 0.919 |
| 9 | C3L-00993 | — | cohortSQ1 | 0.916 |
| 10 | bbeadeec-bb57-4762-8828-3bd1696748fb | — | — | 0.916 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.560 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.540 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.480 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.360 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.310 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.280 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.270 | Inavolisib | — uncovered |
| PEROXISOME | 0.240 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.210 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.150 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.070 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.060 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.050 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.030 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.030 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |